Xenon Pharmaceuticals Inc
XENE
Market Cap$2.55B
Close$
$1.72
94.7% downside
Current Fair Value
94.7% downsideOvervalued by 94.7% based on the discounted cash flow analysis.
Share Statistics
| Market cap | $2.55 Billion |
|---|---|
| Enterprise Value | $2.44 Billion |
| Dividend Yield | $0 (0%) |
| Earnings per Share | $-3.01 |
| Beta | 1.1 |
| Outstanding Shares | 78,687,503 |
Return
| Return on Equity | - |
|---|---|
| Return on Assets | - |
| Return on Invested Capital | - |
Valuation & Multiples
| P/E Ratio | -10.41 |
|---|---|
| PEG | -29.15 |
| Price to Sales | - |
| Price to Book Ratio | 4.09 |
| Enterprise Value to Revenue | 325.89 |
| Enterprise Value to EBIT | -8.34 |
| Enterprise Value to Net Income | -10 |
| Total Debt to Enterprise | 0 |
| Debt to Equity | 0.01 |
Revenue Sources
No data
Insider Trades
ESG Score
No data
About Xenon Pharmaceuticals Inc
CEO: Simon Pimstone